Skip to Main Content
American Flag
LABOR DAY SALE

50% off your first year of any Quiver subscription

...

Use Promo Code:

LABOR26
American Flag
×
Quiver Logo Get a Free Trial on Quiver Premium Today!
Back to News

Surrozen Closes $95.1 Million Private Placement Tranche

None

Surrozen (SRZN) closed the second and final tranche of its March 2025 private placement, generating approximately $95.1 million in gross proceeds before fees and offering expenses. The closing followed FDA clearance of the investigational new drug application for SZN-8141 on October 2, 2026.

The company said its cash, cash equivalents and marketable securities are expected to fund operations into 2029, including the DUET Phase 1b/2a study of SZN-8141 and initial Phase 1b development of SZN-8143.

  • The tranche included approximately 5.7 million common shares, pre-funded warrants for about 2.5 million shares, and Series E warrants for about 4.1 million shares.
  • Series E warrants have an exercise price of $11.54 per share.
  • Surrozen reported approximately 17.8 million common shares outstanding following the closing.
  • First patient dosing in the DUET study is expected in the fourth quarter of 2026, with initial data anticipated in the second half of 2027.
EARLY ACCESS
Receive SRZNW Data Alerts
Real-time alerts on filings, insider trades, and market signals — before everyone else.
Get Alerts →

$SRZNW Hedge Fund Activity

We have seen 2 institutional investors add shares of $SRZNW stock to their portfolio, and 1 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

Add Quiver Quantitative to your preferred sources on Google Google News Logo

Suggested Articles